Merck & Co., Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S5TC52
XNYS · usd
129.56▲ 4.19 (3.34%)
As of 2026-07-02
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)$65.8B
Net Income (TTM)$8.9B
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close125.37
Day's Range125.99 – 129.61
52-Week Range76.66 – 130.29
Volume7.32M
Avg Volume11.59M
Share Statistics
Shares Outstanding2.5B
Employees75.0K
ExchangeXNYS
Listed1949-04-20
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Sales
YoY growth+4.9%+5.0%+3.7%-1.9%
Cost of sales
Selling, general and administrative
Research and development
Restructuring costs
Other (income) expense, net
Income Before Taxes
Taxes on Income
Net Income
% of revenue-26.1%18.1%33.5%28.0%
Less: Net Income Attributable to Noncontrolling Interests
Net Income Attributable to Merck & Co., Inc.
% of revenue-26.0%18.1%33.5%28.0%
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders